mRNA vaccine
Aug 26, 2026
From COVID-19 to Seasonal Influenza: Is mRNA Vaccine Technology Entering Its Second Act?
In August 2026, the U.S. FDA approved mFLUSIVA (mRNA-1010), Moderna's mRNA-based seasonal influenza vaccine, for adults aged 50 and older, the first flu shot in history built on the same messenger-RNA platform that powered the COVID-19 response. It is, by Moderna's own count, the company's fourth approved U.S. prod...
Read More...
Feb 04, 2026
Top 8 Applications of Nanomedicine in Healthcare
As we navigate, the medical landscape is undergoing a silent but profound transformation. We have officially moved beyond the era of "one-size-fits-all" medicine and entered the age of Precision Health, driven largely by the maturity of nanomedicine. While traditional medicine has long relied on macroscopic interve...
Read More...
Feb 02, 2024
Unleashing the Power of mRNA: A Revolutionary Approach to Vaccines and Therapeutics
The progress of mRNA-based therapeutics involves several key stages, including mRNA design, synthesis, entrapment, pharmacodynamics, pharmacokinetics, in vivo and in vitro safety evaluation, manufacturing, and clinical trials. Among these stages, mRNA design and synthesis play pivotal roles in developing mRNA-based...
Read More...
Dec 20, 2022
Fourth FDA Approval for AbbVie’s Vraylar; FDA Approves Ferring’s Adstiladrin for NMIBC; Merck and Moderna’s mRNA Cancer Vaccine Trial; EMA Recommends the CSL’s Gene Therapy for Hemophilia B; CHMP Backs Amicus’ Pompe Disease Therapy; Takeda Announces the Phase 3 AURORA Study Result
AbbVie Secures Fourth FDA Approval for Vraylar AbbVie has received its fourth FDA approval for Vraylar, adding major depressive disorder (MDD) adjunctive therapy to a list that includes schizophrenia and manic and depressive episodes in bipolar disorder. According to AbbVie, the approval makes Vraylar (cariprazi...
Read More...
Mar 22, 2022
Bristol Myers’ Opdivo combo Opdualag for Melanoma; Biogen’s Aduhelm; Marinus’ Ztalmy for CDKL-5 Deficiency Disorder; Merck’s Keytruda + Lynparza; Vitaris’s Breyna; Moderna’s Second COVID-19 Booster Shot; Takeda’s Exkivity; BMS’s First LAG-3 Checkpoint Inhibitor
NHS Grants Fast Track Access to Takeda’s Exkivity Takeda has secured UK approval for its lung cancer therapy Exkivity, with an NHS access deal that could see it prescribed to patients within the next few weeks. The Medicines and Healthcare products Regulatory Agency has granted conditional marketing authorisa...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
